AMITYVILLE, N.Y.--(BUSINESS WIRE)--Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that it received clearance from the FDA to market Tropazone™ lotion, a prescription dermatological product which will be promoted by Hi-Tech’s branded marketing subsidiary, ECR Pharmaceuticals Co., Inc. The product is indicated for the treatment of various dermatological conditions including atopic dermatitis, allergic contact dermatitis, and radiation dermatitis. Tropazone™ utilizes patented Lyphazome™ technology. This delivery system prolongs product activity while enhancing penetration and hydration of the skin. Tropazone™ is patent protected, and two additional patents are pending. Tropazone™ will be promoted by ECR’s 55 person field force beginning February 2010.
